Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
993.11B
Market cap993.11B
Price-Earnings ratio
52.53
Price-Earnings ratio52.53
Dividend yield
0.56%
Dividend yield0.56%
Average volume
3.49M
Average volume3.49M
High today
$1,061.28
High today$1,061.28
Low today
$1,048.25
Low today$1,048.25
Open price
$1,059.61
Open price$1,059.61
Volume
1.61M
Volume1.61M
52 Week high
$1,111.99
52 Week high$1,111.99
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

The current Eli Lilly(LLY) stock price is $1,050.48, with a market capitalization of 993.11B. The stock trades at a price-to-earnings (P/E) ratio of 52.53 and offers a dividend yield of 56.5%.

As of 2025-12-17, Eli Lilly(LLY) stock has fluctuated between $1,048.25 and $1,061.28. The current price stands at $1,050.48, placing the stock +0.2% above today's low and -1.0% off the high.

Eli Lilly(LLY) shares are trading with a volume of 1.61M, against a daily average of 3.49M.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

In the last year, Eli Lilly(LLY) shares hit a 52-week high of $1,111.99 and a 52-week low of $623.78.

LLY News

TipRanks 2h
Eli Lilly’s Phase 2 Study on Imlunestrant: A Potential Game-Changer in Breast Cancer Treatment

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund l...

TipRanks 2h
Eli Lilly’s Pediatric COVID-19 Study on Baricitinib Terminated: Key Insights for Investors

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund l...

24/7 Wall St. 2h
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly

Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly Quick Read Stanley Druckenmiller delivered over 30% average annual returns f...

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
19.4%
Sell
3.2%

More LLY News

The Motley Fool 1d
Is Eli Lilly a Buy Before 2026?

Eli Lilly stock can be a smart addition to a diversified long-term investment portfolio. Eli Lilly (LLY 1.52%) recently announced stellar results from a phase...

Is Eli Lilly a Buy Before 2026?
Benzinga 1d
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Novo Nordisk A/S (NYSE:NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro. Novo Nordisk’s stock was significantly hit when the compa...

TipRanks 1d
Eli Lilly upgraded to Buy from Neutral at Daiwa

Daiwa analyst Narumi Nakagiri upgraded Eli Lilly (LLY) to Buy from Neutral with a $1,230 price target Published first on TheFly – the ultimate source for real-...

Nasdaq 1d
Where Will Eli Lilly Be in 10 Years?

Key Points Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk. Eli Li...

Where Will Eli Lilly Be in 10 Years?
Simply Wall St 2d
Eli Lilly: Revisiting Valuation After a Powerful Multi‑Month Share Price Rally

Market context for Eli Lilly Eli Lilly (LLY) has been quietly grinding higher, with the stock up about 4% over the past month and nearly 39% in the past 3 mont...

Eli Lilly: Revisiting Valuation After a Powerful Multi‑Month Share Price Rally
TipRanks 2d
Bank of America Says Market Isn’t Pricing in Eli Lilly’s Weight-Loss Drug Dominance

The stock market still isn’t pricing in Eli Lilly’s (LLY) dominant position in the market for weight-loss drugs, says Bank of America (BAC). Claim 50% Off TipR...

TipRanks 2d
Eli Lilly price target raised to $1,145 from $951 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Eli Lilly (LLY) to $1,145 from $951 and keeps a Buy rating on the shares. Claim 50% Off TipRanks Premium and In...

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.